financetom
Business
financetom
/
Business
/
RPM International Fiscal Q2 Adjusted Earnings Fall, Sales Rise; Shares Down Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RPM International Fiscal Q2 Adjusted Earnings Fall, Sales Rise; Shares Down Pre-Bell
Mar 11, 2026 12:01 AM

07:02 AM EST, 01/08/2026 (MT Newswires) -- RPM International ( RPM ) reported fiscal Q2 adjusted earnings Thursday of $1.20 per diluted share, down from $1.39 a year earlier.

Analysts polled by FactSet expected $1.41.

Net sales for the quarter ended Nov. 30 were $1.91 billion, compared with $1.85 billion a year earlier.

Analysts surveyed by FactSet expected $1.93 billion.

For fiscal Q3, the company expects sales to increase in the mid-single-digit percentage range compared with prior-year results.

RPM International ( RPM ) said it expects fiscal Q4 consolidated sales to rise in the mid-single-digit range.

The company's shares were down 4.8% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With NIO Shares Tuesday?
What's Going On With NIO Shares Tuesday?
Sep 11, 2024
Chinese EV manufacturer NIO Inc. ( NIO ) shares are trading lower in the premarket session on Tuesday. According to Benzinga Pro, NIO stock has lost over 46% in the past year. Investors can gain exposure to the stock via Invesco Golden Dragon China ETF ( PGJ ) and KraneShares Electric Vehicles and Future Mobility Index ETF . Today, Chinese automotive powerhouse...
Viridian Therapeutics Says Potential Thyroid Eye Disease Drug Meets Endpoints in Phase 3 Trial
Viridian Therapeutics Says Potential Thyroid Eye Disease Drug Meets Endpoints in Phase 3 Trial
Sep 11, 2024
08:14 AM EDT, 09/10/2024 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Tuesday that a phase 3 clinical trial of VRDN-001 or veligrotug, a potential treatment of active thyroid eye disease, met all primary and secondary endpoints at 15 weeks after five infusions. Overall, 67% of patients receiving the intravenously delivered drug achieved proptosis response and a 2-point reduction...
Montrose Environmental Acquires Colorado-Based Origins Laboratory
Montrose Environmental Acquires Colorado-Based Origins Laboratory
Sep 11, 2024
08:25 AM EDT, 09/10/2024 (MT Newswires) -- Montrose Environmental Group ( MEG ) said Tuesday it has acquired Origins Laboratory, a Denver, Colorado-based environmental laboratory. Financial terms of the acquisition weren't disclosed. The company will merge Origins into its measurement and analysis segment, Montrose added. Origins will operate as part of the company's enthalpy analytical unit. Shares of the company...
Schlumberger Claims Successful Sustainable Lithium Production at Scale at Clayton Valley Facility
Schlumberger Claims Successful Sustainable Lithium Production at Scale at Clayton Valley Facility
Sep 11, 2024
08:14 AM EDT, 09/10/2024 (MT Newswires) -- Schlumberger ( SLB ) said Tuesday it has demonstrated successful sustainable lithium production at scale at its Clayton Valley, Nevada plant. Schlumberger ( SLB ) said its proprietary integrated approach, which combines its subsurface expertise with surface engineering of advanced technologies that include direct lithium extraction, is capable of producing lithium 500 times...
Copyright 2023-2026 - www.financetom.com All Rights Reserved